Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Marts 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.1k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • H Offline
    H Offline
    hda
    wrote on sidst redigeret af
    #753

    1 måned til Q1. Det bliver anderledes spændende

    1 Reply Last reply
    0
    • B Offline
      B Offline
      bibob
      wrote on sidst redigeret af
      #754

      Det ser ud til at sælgerne bliver i mindretal nu. Nu er vi da næsten
      status Q

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #755

        @ Solsen - lets hope we can get a similar article on CAR-T targeting BCMA, that would put me more at ease...

        1 Reply Last reply
        0
        • M Offline
          M Offline
          mobbyduck1
          wrote on sidst redigeret af
          #756

          @hda, ja Q1 med ROW tal der inkluderer fuldt 3 mdr salg i JApan, 4 linje i UK, samt Canada, det skal nok give lidt ekstra
          i kassen

          1 Reply Last reply
          0
          • H Offline
            H Offline
            hda
            wrote on sidst redigeret af
            #757

            Lige præcis mobbyduck1. Første gang vi får Japan med for hele kvartalet

            1 Reply Last reply
            0
            • A Offline
              A Offline
              AaBforever
              wrote on sidst redigeret af
              #758

              Ja det bliver spændende 17. april.

              1 Reply Last reply
              0
              • A Offline
                A Offline
                AaBforever
                wrote on sidst redigeret af
                #759

                Hvor langt vi kommer over 400 mill. i Q1

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #760

                  after reaching €50mio, Dara lost Orphan status in Germany, leading to "eine Bekanntmachung" from the "Bundesministerium für Gesundheit" 😉 https://www.bundesanzeiger.de/ebanzwww/wexsservlet?session.sessionid=16a142094cdbe8edd5841e4fa803c0b8&page.navid=detailsearchlisttodetailsearchdetail&fts_search_list.selected=d747026b6b3fc404&fts_search_list.destHistoryId=16642 https://www.g-ba.de/informationen/nutzenbewertung/307/#tab/beschluesse

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #761

                    pdf https://www.g-ba.de/downloads/39-261-3222/2018-02-15_AM-RL_XII_Daratumumab_D-310_BAnz.pdf

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #762

                      not sure if it has any further practical implications , but the document shows a good insight in costs for the different combinations, eg Dara Len Dex 246.965,89 €, vs Dara Bor Dex 185.522,46 € "

                      1 Reply Last reply
                      0
                      • H Offline
                        H Offline
                        hda
                        wrote on sidst redigeret af
                        #763

                        Ekstra Bladet om Darzalex salget i US i februar http://borsen.dk/nyheder/virksomheder/artikel/1/360281/genmab_darzalex-salget_faldt_i_usa_i_februar.html?utm_source=forside&utm_campaign=nyhed_03

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #764

                          Solsen, har du kendskab til et sammenligningsgrundlag for OS i ALL? 12,9 mdr. lyder ikke af meget, men spm er hvad man har opnået med andre midler.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #765

                            ALL er vist ret aggressiv - her Blincito data ved godkendelse. Ved ikke om patientgrundlaget er det samme:

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #766

                              Document Moved

                              favicon

                              (www.amgen.com)

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #767

                                The approval is based on results from the TOWER study, which found that BLINCYTO demonstrated a superior improvement in median OS over standard of care (SOC) chemotherapy, nearly doubling median OS. The study showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus four months (95 percent CI: 2.9, 5.3) for SOC (hazard ratio for death=0.71; p=0.012). The approval is also based on data from the Phase 2 ALCANTARA study, which evaluated the efficacy of BLINCYTO in adult pat

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #768

                                  Blincyto er CD19/CD3 så nok noget nær bedste sammenligning

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #769

                                    with Ph+ relapsed or refractory B-cell precursor ALL.

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sibelius
                                      wrote on sidst redigeret af
                                      #770

                                      TIlgengæld skriver Berlingske i dag i ena rtikel om stigende udgifter til ny medicin i DK at omkostningerne til Darzalex steg mere end 500% fra 2016 til 2017. Der blev købt for DKK 138 millioner i 2017.

                                      1 Reply Last reply
                                      0
                                      • BulderB Offline
                                        BulderB Offline
                                        Bulder
                                        wrote on sidst redigeret af
                                        #771

                                        Ja, det ville have været rart med en kontrolgruppe, der fik SOC i car-t studiet. Ved du hvad det der Philadelphia chromosome-negative-halløj indebærer? Er de hårdere ramt i Blincytostudiet?

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #772

                                          Ved det ikke Bulder, men umiddelbart vil jeg tro at de er hårdere ramt, men har som sagt intet at have det i

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger